Provided by Tiger Fintech (Singapore) Pte. Ltd.

Emergent BioSolutions

5.53
-0.0900-1.60%
Volume:1.37M
Turnover:7.45M
Market Cap:299.64M
PE:-1.54
High:5.70
Open:5.61
Low:5.26
Close:5.62
Loading ...

Gold Gains 1%; Halliburton Posts Weak Q3 Results

Benzinga
·
08 Nov 2024

Emergent Biosolutions Is Maintained at Buy by Benchmark

Dow Jones
·
07 Nov 2024

Emergent BioSolutions rises 23.7%

TIPRANKS
·
07 Nov 2024

Emergent BioSolutions Inc : Benchmark Raises Target Price to $12

THOMSON REUTERS
·
07 Nov 2024

New Strong Buy Stocks for November 7th

Zacks
·
07 Nov 2024

BUZZ-Emergent rises on improved 2024 sales view, narrower loss forecast

Reuters
·
07 Nov 2024

Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript

Motley Fool Transcribing
·
07 Nov 2024

Emergent BioSolutions announces brincidofovir trial in Africa

TIPRANKS
·
07 Nov 2024

Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates

Zacks
·
07 Nov 2024

Emergent BioSolutions Q3 2024 Adj. EPS $1.37 Beats $0.14 Estimate, Sales $293.800M Miss $297.500M Estimate

Benzinga
·
07 Nov 2024

BRIEF-Emergent Biosolutions supports new clinical trial evaluating the safety and efficacy of Brincidofovir in treating Mpox virus across Africa

Reuters
·
07 Nov 2024

Emergent Biosolutions: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Emergent BioSolutions Inc - Study to Evaluate Safety and Efficacy of Tembexa for Mpox

THOMSON REUTERS
·
07 Nov 2024

Emergent BioSolutions Inc - Mosa Trial to Begin in Drc and Neighboring Countries

THOMSON REUTERS
·
07 Nov 2024

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

THOMSON REUTERS
·
07 Nov 2024

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

GlobeNewswire
·
07 Nov 2024